Can an experimental pill slow a rare brain disease? a trial puts ATH434 to the test.

NCT ID NCT07729852

Not yet recruiting Disease control Sponsor: Alterity Therapeutics Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This trial is investigating whether ATH434, an experimental drug taken twice daily as a tablet, can help control multiple system atrophy (MSA), a rare and progressive brain disorder. The study enrolls people who have already completed a prior phase 2 trial of ATH434 and may benefit from continued treatment. Researchers are primarily monitoring safety, side effects, and how long participants stay on the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ATH434, an experimental drug taken as a tablet twice daily
What this could lead to: If this trial succeeds, it could point toward a treatment that slows or manages multiple system atrophy, a currently untreatable neurodegenerative disease.
What could go wrong: This is a small, early-stage study with only 5 participants, so results may not apply broadly. The drug's long-term safety and effectiveness are still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SYSTEM ATROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple system atrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SYSTEM ATROPHY

Contacts and locations

Locations

Centre Hospitalier Universitaire de Bordeaux

Bordeaux, New Aquitaine, 33076, France
Hôpital Pierre-Paul Riquet

Toulouse, Midi-Pyrenees, 31300, France
Hôpital Universitaire Pitié Salpêtrière

Paris, Île-de-France Region, 75013, France
Hôpital de la Timone

Marseille, Provence-Alpes-Côte d'Azur Region, 13005, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.